IDEXX Laboratories Inc (IDXX) stock
IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$676.21−13.44 (-1.95%)
Close on Nov 20, 2026Market cap $53.27BP/E 47.6Yield –
IDEXX Laboratories revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
IDEXX Laboratories's revenue for the twelve months ending Jun 30, 2026 was $4.55B, up 12.8% year over year. For fiscal 2025 it was $4.30B, up 10.4% from the year before. Over ten years it grew 10.4% a year on average. The highest annual figure on record is $4.30B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.30B | +10.4% |
| FY2024 | Dec 31, 2024 | $3.90B | +6.5% |
| FY2023 | Dec 31, 2023 | $3.66B | +8.7% |
| FY2022 | Dec 31, 2022 | $3.37B | +4.7% |
| FY2021 | Dec 31, 2021 | $3.22B | +18.8% |
| FY2020 | Dec 31, 2020 | $2.71B | +12.5% |
| FY2019 | Dec 31, 2019 | $2.41B | +8.8% |
| FY2018 | Dec 31, 2018 | $2.21B | +12.4% |
| FY2017 | Dec 31, 2017 | $1.97B | +10.9% |
| FY2016 | Dec 31, 2016 | $1.78B | +10.8% |
| FY2015 | Dec 31, 2015 | $1.60B | +7.8% |
| FY2014 | Dec 31, 2014 | $1.49B | +7.9% |
| FY2013 | Dec 31, 2013 | $1.38B | +6.5% |
| FY2012 | Dec 31, 2012 | $1.29B | +6.1% |
| FY2011 | Dec 31, 2011 | $1.22B | +10.4% |
| FY2010 | Dec 31, 2010 | $1.10B | +7.0% |
| FY2009 | Dec 31, 2009 | $1.03B | +0.7% |
| FY2008 | Dec 31, 2008 | $1.02B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.22B | +9.7% |
| Q1 FY2026 | Mar 31, 2026 | $1.14B | +14.3% |
| Q4 FY2025 | Dec 31, 2025 | $1.09B | +14.3% |
| Q3 FY2025 | Sep 30, 2025 | $1.11B | +13.3% |
| Q2 FY2025 | Jun 30, 2025 | $1.11B | +10.6% |
| Q1 FY2025 | Mar 31, 2025 | $998.43M | +3.6% |
| Q4 FY2024 | Dec 31, 2024 | $954.29M | +5.8% |
| Q3 FY2024 | Sep 30, 2024 | $975.54M | +6.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.00B | +6.4% |
| Q1 FY2024 | Mar 31, 2024 | $964.10M | +7.1% |
| Q4 FY2023 | Dec 31, 2023 | $901.60M | +8.8% |
| Q3 FY2023 | Sep 30, 2023 | $915.53M | +8.8% |
| Q2 FY2023 | Jun 30, 2023 | $943.63M | +9.7% |
| Q1 FY2023 | Mar 31, 2023 | $900.20M | +7.6% |
| Q4 FY2022 | Dec 31, 2022 | $828.57M | +3.4% |
| Q3 FY2022 | Sep 30, 2022 | $841.66M | +3.9% |
| Q2 FY2022 | Jun 30, 2022 | $860.55M | +4.2% |
| Q1 FY2022 | Mar 31, 2022 | $836.55M | +7.6% |
| Q4 FY2021 | Dec 31, 2021 | $801.09M | +11.1% |
| Q3 FY2021 | Sep 30, 2021 | $810.42M | +12.3% |
| Q2 FY2021 | Jun 30, 2021 | $826.14M | +29.6% |
| Q1 FY2021 | Mar 31, 2021 | $777.71M | +24.2% |
| Q4 FY2020 | Dec 31, 2020 | $720.94M | +19.1% |
| Q3 FY2020 | Sep 30, 2020 | $721.79M | +19.2% |
| Q2 FY2020 | Jun 30, 2020 | $637.59M | +2.8% |
| Q1 FY2020 | Mar 31, 2020 | $626.34M | +8.7% |
| Q4 FY2019 | Dec 31, 2019 | $605.45M | +10.2% |
| Q3 FY2019 | Sep 30, 2019 | $605.30M | +11.0% |
| Q2 FY2019 | Jun 30, 2019 | $620.10M | +6.8% |
| Q1 FY2019 | Mar 31, 2019 | $576.06M | +7.1% |
| Q4 FY2018 | Dec 31, 2018 | $549.39M | +8.5% |
| Q3 FY2018 | Sep 30, 2018 | $545.45M | +10.9% |
| Q2 FY2018 | Jun 30, 2018 | $580.75M | +14.1% |
| Q1 FY2018 | Mar 31, 2018 | $537.66M | +16.4% |
| Q4 FY2017 | Dec 31, 2017 | $506.12M | +14.2% |
| Q3 FY2017 | Sep 30, 2017 | $491.98M | +9.7% |
| Q2 FY2017 | Jun 30, 2017 | $508.94M | – |
| Q1 FY2017 | Mar 31, 2017 | $462.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $443.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $448.31M | – |
See a number that looks wrong?